Public Employees Retirement Association of Colorado Acquires New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Public Employees Retirement Association of Colorado bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 15,012 shares of the company’s stock, valued at approximately $303,000.

A number of other institutional investors have also added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in shares of Hims & Hers Health during the second quarter valued at approximately $808,000. Hsbc Holdings PLC lifted its holdings in Hims & Hers Health by 140.7% during the second quarter. Hsbc Holdings PLC now owns 138,224 shares of the company’s stock worth $2,727,000 after buying an additional 80,810 shares during the period. Amalgamated Bank boosted its position in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after acquiring an additional 2,354 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in shares of Hims & Hers Health by 1,391.3% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 149,176 shares of the company’s stock valued at $3,012,000 after acquiring an additional 139,173 shares during the period. Finally, Virtu Financial LLC raised its position in shares of Hims & Hers Health by 265.9% in the 2nd quarter. Virtu Financial LLC now owns 150,911 shares of the company’s stock worth $3,047,000 after acquiring an additional 109,666 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,335 shares of Hims & Hers Health stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total transaction of $47,353.80. Following the completion of the transaction, the insider now owns 169,144 shares in the company, valued at approximately $3,430,240.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Soleil Boughton sold 2,335 shares of the firm’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total transaction of $47,353.80. Following the sale, the insider now owns 169,144 shares in the company, valued at approximately $3,430,240.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 731,473 shares of company stock valued at $12,671,277. 17.71% of the stock is owned by insiders.

Hims & Hers Health Stock Up 0.3 %

Shares of NYSE:HIMS opened at $17.76 on Friday. The business has a 50-day moving average price of $16.93 and a 200-day moving average price of $17.16. The stock has a market cap of $3.81 billion, a price-to-earnings ratio of -1,776.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 52-week low of $5.65 and a 52-week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.03) EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on HIMS shares. Jefferies Financial Group raised their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, June 27th. Bank of America cut their price objective on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, September 13th. TD Cowen increased their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Piper Sandler reaffirmed a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a report on Tuesday, August 6th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective for the company. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.86.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.